Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma, a Real-World Experience

被引：8
|
作者：
Hultcrantz, Malin [1 ]
Orozco, Jennifer [2 ]
Peterson, Tim J. [2 ]
Derkach, Andriy [3 ]
Hassoun, Hani [1 ]
Korde, Neha [1 ]
Lu, Sydney X. [1 ]
Mailankody, Sham [1 ]
Patel, Dhwani [1 ]
Shah, Urvi A. [1 ]
Tan, Carlyn [1 ,4 ]
Maclachlan, Kylee H. [1 ]
Chung, David J. [5 ]
Landau, Heather J. [6 ]
Shah, Gunjan L. [6 ]
Lahoud, Oscar B. [6 ]
Scordo, Michael [6 ]
Landgren, Ola [7 ]
Giralt, Sergio [8 ]
Lesokhin, Alexander [4 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Dept Med, Myeloma Serv, New York, NY USA
[2] Mem Sloan Kettering Canc Ctr, Dept Pharm, Dept Med, New York, NY USA
[3] Mem Sloan Kettering Canc Ctr, Dept Biostat & Epidemiol, New York, NY USA
[4] Mem Sloan Kettering Canc Ctr, New York, NY USA
[5] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY USA
[6] Mem Sloan Kettering Canc Ctr, Dept Med, Adult Bone Marrow Transplant Serv, New York, NY USA
[7] Univ Miami, Dept Med, Myeloma Program, Sylvester Comprehens Canc Ctr, Miami, FL USA
[8] Mem Sloan Kettering Canc Ctr, Dept Med, Adult Bone Marrow Transplant Serv, New York, NY USA
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-15344
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1644
引用
收藏
页数：5
相关论文
共 50 条
  • [31] Safety and Efficacy of Teclistamab in Patients with Relapsed/ Refractory Multiple Myeloma: A Real-World Experience
    Dima, Danai
    Davis, James A.
    Ahmed, Nausheen
    Jia, Xuefei
    Sannareddy, Aishwarya
    Shaikh, Hira
    Shune, Leyla
    Kaur, Gurbakhash
    Khouri, Jack
    Afrough, Aimaz
    Strouse, Christopher
    Lochner, Jonathan
    Mahmoudjafari, Zahra
    Raza, Shahzad
    Valent, Jason
    Anderson Jr, Larry D.
    Anwer, Faiz
    Abdallah, Al-Ola
    Hashmi, Hamza
    [J]. TRANSPLANTATION AND CELLULAR THERAPY, 2024, 30 (03):
  • [32] Compassionate Use of Belantamab Mafodotin for Treatment of Patients with Relapsed/Refractory Multiple Myeloma Heavily Treated. Spanish Experience
    Alegre, Adrian
    Benzo Callejo, Gonzalo
    Alonso Fernandez, Rafael
    Martinez-Lopez, Joaquin
    Jimenez-Ubieto, Ana
    Cuellar, Clara
    Askari, Elham
    Prieto, Elena
    Alaez, Concha
    Aguado, Beatriz
    Velasco, Alberto
    Krsnik, Isabel
    Llorente, Laura
    Munoz-Linares, Cristina
    Morales, Ana
    Gimenez Mesa, Eugenio
    Iglesias, Rebeca
    Martinez-Chamorro, Carmen
    Alonso, Arancha
    Jimenez-Montes, Carmen
    Jesus Blanchard, Maria
    [J]. BLOOD, 2021, 138 : 3775 - +
  • [33] EMA Review of Belantamab Mafodotin (Blenrep) for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma
    Tzogani, Kyriaki
    Penttil, Karri
    Lahteenvuo, Johanna
    Lapvetelainen, Tuomo
    Lopez Anglada, Lucia
    Prieto, Carolina
    Garcia-Ochoa, Blanca
    Enzmann, Harald
    Gisselbrecht, Christian
    Delgado, Julio
    Pignatti, Francesco
    [J]. ONCOLOGIST, 2021, 26 (01): : 70 - 76
  • [34] Effectiveness and Safety of Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma in RealLife Setting: The ALFA Study
    Roussel, Murielle
    Texier, Nathalie
    Germain, Raphael
    Sapra, Sandhya
    Paka, Prani
    Kerbouche, Naima
    Colin, Xavier
    Leleu, Xavier
    [J]. BLOOD, 2022, 140 : 4261 - 4263
  • [35] Real-World Outcomes with Panobinostat in Patients with Relapsed/Refractory Multiple Myeloma
    Biran, Noa
    Vesole, David H.
    Zhang, Shijia
    Richter, Joshua R.
    Kuo, Yen-Hong
    Schmidt, Linda
    McBride, Laura
    Anand, Palka
    Ivanovski, Kristin
    Pierre, Amy
    Kumka, Susan
    Cuccurullo, Carmela
    Siegel, David S.
    [J]. BLOOD, 2016, 128 (22)
  • [36] Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM)
    Lonial, Sagar
    Nooka, Ajay K.
    Thulasi, Praneetha
    Badros, Ashraf Z.
    Jeng, Bennie H.
    Callander, Natalie S.
    Potter, Heather A.
    Sborov, Douglas
    Zaugg, Brian E.
    Popat, Rakesh
    Degli Esposti, Simona
    Byrne, Julie
    Opalinska, Joanna
    Baron, January
    Piontek, Trisha
    Gupta, Ira
    Dana, Reza
    Farooq, Asim V.
    Colby, Kathryn
    Jakubowiak, Andrzej
    [J]. BLOOD CANCER JOURNAL, 2021, 11 (05)
  • [37] OUTCOMES OF IDECABTAGENE VICLEUCEL IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA PREVIOUSLY TREATED WITH BELANTAMAB MAFODOTIN
    Melody, Megan
    Przybylski, Daniel
    Robinson, Adam
    Lin, Adam
    Gordon, Leo
    Adekola, Kehinde
    Singhal, Seema
    Mehta, Jayesh
    Moreira, Jonathan
    [J]. BONE MARROW TRANSPLANTATION, 2023, 58 (SUPP1) : 210 - 211
  • [38] REAL-WORLD EXPERIENCE OF LENALIDOMIDE/DEXAMETHASONE TREATMENT FOR REFRACTORY/RELAPSED MULTIPLE MYELOMA (RRMM) PATIENTS
    Tognazzi, L.
    Rivolti, E.
    Quaresima, M.
    Labbozzetta, S.
    Gamberi, B.
    Merli, F.
    [J]. HAEMATOLOGICA, 2017, 102 : 137 - 137
  • [39] Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM)
    Sagar Lonial
    Ajay K. Nooka
    Praneetha Thulasi
    Ashraf Z. Badros
    Bennie H. Jeng
    Natalie S. Callander
    Heather A. Potter
    Douglas Sborov
    Brian E. Zaugg
    Rakesh Popat
    Simona Degli Esposti
    Julie Byrne
    Joanna Opalinska
    January Baron
    Trisha Piontek
    Ira Gupta
    Reza Dana
    Asim V. Farooq
    Kathryn Colby
    Andrzej Jakubowiak
    [J]. Blood Cancer Journal, 11
  • [40] Ocular Toxicity of Belantamab Mafodotin, an Oncological Perspective of Management in Relapsed and Refractory Multiple Myeloma
    Wahab, Ahsan
    Rafae, Abdul
    Mushtaq, Kamran
    Masood, Adeel
    Ehsan, Hamid
    Khakwani, Maria
    Khan, Aqsa
    [J]. FRONTIERS IN ONCOLOGY, 2021, 11
12345